Press release
Investigation announced for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Investigation over potential Wrongdoing
An investigation on behalf of investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares over potential wrongdoing.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Reata Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Plano, TX based Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Reata Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $53.58 million in 2018 to $26.51 million in 2019, and that its Net Loss increased from $80.54 million in 2018 to $290.17 million in 2019.
Shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) declined from $257.96 per share in February 2020 to as low as $113.01 per share on March 23, 2020.
On July 13, 2020, NASDAQ: RETA shares closed at $153.03 per share.
Those who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Investigation over potential Wrongdoing here
News-ID: 2154418 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Long-Term Investors in shares of WEBTOON Entertainme …
An investigation on behalf of current long-term investors in shares of WEBTOON Entertainment Inc. (NASDAQ: WBTN) concerning potential breaches of fiduciary duties by certain directors of WEBTOON Entertainment Inc. was announced.
Investors who are current long term investors in WEBTOON Entertainment Inc. (NASDAQ: WBTN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
Deadline on Nov. 19th coming up in Lawsuit for Investors who lost money with Dom …
A deadline is coming up on November 19, 2024 in the lawsuit filed for certain investors of Domino's Pizza, Inc. (NYSE: DPZ) over alleged securities laws violations by Domino's Pizza, Inc.
Investors who purchased shares of Domino's Pizza, Inc. (NYSE: DPZ) have certain options and there are strict and short deadlines running. Deadline: November 19, 2024. NYSE: DPZ stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Lawsuit filed for Investors who lost money with shares of United Parcel Service, …
An investor, who purchased shares of United Parcel Service, Inc. (NYSE: UPS), filed a lawsuit over alleged violations of Federal Securities Laws by United Parcel Service, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of United Parcel Service, Inc. (NYSE: UPS) have certain options and for certain investors are short and strict deadlines running. Deadline: December 9, 2024. NYSE: UPS investors should contact the Shareholders…
Long-Term Investors in shares of Palo Alto Networks, Inc. (NASDAQ: PANW) should …
An investigation was announced for current long-term investors in shares of Palo Alto Networks, Inc. (NASDAQ: PANW) concerning potential breaches of fiduciary duties by certain directors of Palo Alto Networks, Inc.
Investors who are current long term investors in Palo Alto Networks, Inc. (NASDAQ: PANW) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current…
More Releases for Reata
Investigation for Long-Term Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc.
Investors who are current long term investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RETA stocks follows a lawsuit filed against Reata Pharmaceuticals, Inc.…
Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced over potential securities laws violations by Reata Pharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were…
Lawsuit filed for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares
An investor, who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), filed a lawsuit iover alleged violations of Federal Securities Laws by Reata Pharmaceuticals, Inc.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and for certain investors are short and strict deadlines running. Deadline: December 14, 2020. NASDAQ: RETA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On August 10, 2020,…
Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential securities laws violations by Reata Pharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were…
Ataxia Therapeutics Pipeline Analysis 2018 | Reata Pharmaceuticals, Inc., Voyage …
Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk.
Download the sample report @ https://www.pharmaproff.com/request-sample/1078
The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in…
Diabetic Nephropathy market 2020 | Pfizer, Inc., Merck & Co., Inc., Sanofi, Reat …
Diabetic nephropathy is known as the most significant impediment occurring in the kidney glomerulus which render the patient morbid or even worse in majority of the cases. Characterized by macroalbuminuria, diabetic nephropathy is diagnosed when more than 300 milligrams of albumin are present in the urine in a day. The global market for diabetic nephropathy was valued at US$ 2,262.2 million in 2014. Registering a steady CAGR of 5.6%, the…
